Detalhe da pesquisa
1.
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
Lancet HIV
; 11(4): e211-e221, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538160
2.
Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age.
AIDS
; 36(4): 525-532, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34873089
3.
Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study.
Lancet HIV
; 9(1): e24-e31, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34883066
4.
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.
J Pediatric Infect Dis Soc
; 10(2): 201-204, 2021 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-32448902
5.
Pharmacokinetics and safety of maraviroc in neonates.
AIDS
; 35(3): 419-427, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33252481
6.
Association of Virologic Failure and Nonnucleoside Reverse Transcriptase Inhibitor Resistance Found in Antiretroviral-Naive Children Infected With Human Immunodeficiency Virus and Given Efavirenz-Based Treatment.
J Pediatric Infect Dis Soc
; 9(2): 261-264, 2020 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31194860
7.
Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years.
J Acquir Immune Defic Syndr
; 81(4): 473-480, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31241542
8.
Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis.
AIDS
; 33(14): 2197-2203, 2019 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31689263
9.
CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection.
AIDS
; 31(8): 1129-1136, 2017 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28323755
10.
Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A.
Pediatr Infect Dis J
; 34(2): 162-7, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25232777
11.
Towards early inclusion of children in tuberculosis drugs trials: a consensus statement.
Lancet Infect Dis
; 15(6): 711-20, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25957923
12.
Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents.
AIDS
; 25(12): 1489-96, 2011 Jul 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-21610486
13.
Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children.
J Allergy Clin Immunol
; 119(3): 747-50, 2007 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17336619
14.
Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140).
J Allergy Clin Immunol
; 118(2): 518-21, 2006 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16890780